Find comprehensive information on pancreatic tumor diagnosis, including clinical documentation, medical coding (ICD-10 codes C25, D13.6), healthcare guidelines, and treatment options. Learn about symptoms, staging (TNM), pathology reports, and the role of imaging (CT scan, MRI) in pancreatic cancer diagnosis. This resource provides valuable insights for healthcare professionals, patients, and researchers seeking information on pancreatic neoplasms, pancreatic adenocarcinoma, and islet cell tumors. Explore the latest advancements in diagnosis and management of pancreatic tumors.
Also known as
Malignant neoplasm of pancreas
Cancerous tumors affecting the pancreas.
Benign neoplasm of pancreas
Non-cancerous tumors found in the pancreas.
Secondary malignant neoplasm of pancreas
Cancer that has spread to the pancreas from another site.
Neoplasm of uncertain behavior of pancreas
Pancreatic tumors with unknown potential for malignancy.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the pancreatic tumor malignant?
When to use each related code
| Description |
|---|
| Pancreatic Tumor |
| Pancreatic Cyst |
| Pancreatitis |
Coding pancreatic tumor without specifying site (head, body, tail) leads to inaccurate DRG assignment and reimbursement.
Incorrectly coding tumor behavior (benign, uncertain, malignant) impacts treatment planning and cancer registry data.
Failing to code secondary malignancy in the pancreas if present can underestimate patient complexity and resource utilization.
Patient presents with concerning symptoms suggestive of pancreatic tumor, including abdominal pain, unexplained weight loss, jaundice, and new-onset diabetes. Physical examination may reveal abdominal tenderness, palpable mass, or signs of ascites. Differential diagnosis includes pancreatic adenocarcinoma, pancreatic neuroendocrine tumor (PanNET), intraductal papillary mucinous neoplasm (IPMN), and solid pseudopapillary neoplasm (SPN). Diagnostic workup includes laboratory tests such as complete blood count (CBC), comprehensive metabolic panel (CMP), liver function tests (LFTs), tumor markers (CA 19-9, CEA), and imaging studies such as abdominal ultrasound, computed tomography (CT) scan with contrast, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and potentially endoscopic retrograde cholangiopancreatography (ERCP) with biopsy. Biopsy confirmation is essential for definitive diagnosis and histopathological characterization. Treatment options depend on tumor type, stage, and location, and may include surgical resection (Whipple procedure, distal pancreatectomy), chemotherapy, radiation therapy, targeted therapy, and palliative care. Patient education regarding prognosis, treatment options, potential complications, and follow-up care is crucial. ICD-10 codes (C25.0-C25.9) are applicable depending on specific tumor type and location. Medical billing and coding for pancreatic tumor evaluations and treatments should be accurately documented for proper reimbursement. Ongoing surveillance and monitoring are essential for early detection of recurrence or metastasis.